$0.34
9.76% yesterday
Nasdaq, May 20, 10:12 pm CET
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

FibroGen, Inc. Stock price

$0.34
+0.06 20.06% 1M
-0.01 1.66% 6M
-0.19 35.00% YTD
-0.86 71.32% 1Y
-8.26 96.00% 3Y
-37.25 99.08% 5Y
-17.66 98.09% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.03 9.76%
ISIN
US31572Q8087
Symbol
FGEN
Sector
Industry

Key metrics

Market capitalization $34.78m
Enterprise Value $134.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.31
P/S ratio (TTM) P/S ratio 0.34
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -38.60%
Revenue (TTM) Revenue $102.85m
EBIT (operating result TTM) EBIT $-30.17m
Free Cash Flow (TTM) Free Cash Flow $-76.29m
Cash position $33.61m
EPS (TTM) EPS $-0.10
P/E forward negative
P/S forward 3.53
EV/Sales forward 13.64
Short interest 4.38%
Show more

Is FibroGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

FibroGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a FibroGen, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a FibroGen, Inc. forecast:

Buy
50%
Hold
50%

Financial data from FibroGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
103 103
39% 39%
100%
- Direct Costs 5.56 5.56
86% 86%
5%
97 97
23% 23%
95%
- Selling and Administrative Expenses 53 53
44% 44%
52%
- Research and Development Expense 72 72
71% 71%
70%
-28 -28
87% 87%
-27%
- Depreciation and Amortization 2.20 2.20
72% 72%
2%
EBIT (Operating Income) EBIT -30 -30
87% 87%
-29%
Net Profit -10 -10
96% 96%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about FibroGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

FibroGen, Inc. Stock News

Neutral
Seeking Alpha
8 days ago
FibroGen, Inc. (NASDAQ:FGEN ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - Chief Executive Officer David DeLucia - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Matthew Keller - H.C. Wainwright Operator Good day and thank you for standing by.
Neutral
GlobeNewsWire
8 days ago
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments.
Neutral
GlobeNewsWire
13 days ago
Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. I...
More FibroGen, Inc. News

Company Profile

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Head office United States
CEO Thane Wettig
Employees 225
Founded 1993
Website www.fibrogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today